CD274 and neoplasm: Although biomarkers, including tumour mutation burden, programmed death ligand 1 (PD-L1) expression, lymphocyte infiltration rate, and tumour-immune phenotypes, were identified, their clinical efficacy for predicting treatment response remains unconfirmed and controversial [157,158].